Table 3.

Adjusted effect of 8 compared with 12 weeks of ledipasvir/sofosbuvir on SVR12 among 2653 HCV-infected individuals eligible for 8 weeks

	Adjusted RR (95% CI)	P	P interaction
Overall	1.00 (0.98–1.02)	0.92
Race			0.90
Black	1.00 (0.95–1.04)	0.88
Non-black	1.00 (0.98–1.02)	0.96
Age in years			0.064
<50	1.06 (0.99–1.14)	0.09
≥50	0.99 (0.97–1.01)	0.40

SVR, sustained virologic response; HCV, hepatitis C virus; RR, risk ratio; CI, confidence interval. Eligibility for 8 weeks was defined as genotype 1, treatment-naive, no cirrhosis (i.e., transient elastography <12 kPa if available, else FIB-4 ≤5.88), HIV-uninfected, and HCV RNA <6 million IU/mL. Excludes 109 with no HCV RNA test done after 11 weeks following end of treatment. RRs obtained from Poisson models with robust variance, with main terms for treatment duration, age, and race, and interaction terms to assess differences in the effect of treatment duration between subgroups.